Profiel
Charles A.
McWherter worked as the VP & Head-Cardiovascular Therapeutics Areas at Pfizer Inc. from 2003 to 2007.
Prior to that, he served as the Vice President-Drug Discovery at Sugen, Inc. from 2001 to 2003.
Currently, he is the President-Research & Development at CymaBay Therapeutics, Inc. since 2022.
Dr. McWherter holds a doctorate degree from Cornell University.
Eerdere bekende functies van Charles McWherter
| Bedrijven | Functie | Einde |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 22-03-2024 |
| PFIZER, INC. | Corporate Officer/Principal | 01-01-2007 |
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Corporate Officer/Principal | 01-01-2003 |
Opleiding van Charles McWherter
| Cornell University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
